Danaher announced Wednesday that its wholly owned subsidiary DH Europe Finance has priced its offering of $3.97 billion senior notes.
Proceeds will be used to fund part of the company's planned $21.4 billion acquisition of GE Life Sciences' Biopharma business.
The offering includes $700 million of 2.05 percent senior notes due in 2022; $700 million of 2.2 percent senior notes due in 2024; $800 million of 2.6 percent senior notes due in 2029; $900 million of 3.25 percent senior notes due in 2039; and $900 million of 3.4 percent senior notes due in 2049.
The offering is expected to close Nov. 7.
In September, Washington, DC-based Danaher offered �6.2 billion ($6.88 billion) in senior notes also to fund, in part, the GE Biopharma deal.
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.